Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173

Trial Profile

Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veldoreotide (Primary) ; Octreotide
  • Indications Acromegaly
  • Focus Pharmacodynamics
  • Sponsors Aspireo Pharmaceuticals
  • Most Recent Events

    • 31 May 2016 According to a Strongbridge Biopharma media release, data from this study were presented at the 18th European Congress of Endocrinology.
    • 30 Apr 2014 New trial record
    • 22 Apr 2014 Results reported in an Aspireo Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top